Bracing for a Run of Major Patent Expirations
More than $20 billion of branded drugs are scheduled to lose patent protection over the next four years, which translates into a $5 billion opportunity for generic drug makers, according to Cowen & Co. Following is a chart of major drug patent/ exclusivity expirations 2000-2001
You may also be interested in...
After double-digit growth in formulation sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which is now transferred to its fully owned subsidiary for $48m.
The European Commission has updated its rolling plan. It now looks as if current member state rules for non-medical products could persist beyond the 26 May 2021 deadline.
GSK launches a 100% natural saline spray in the UK to compliment its Piri hayfever brand portfolio.